Jonathan Steckbeck is the founder of Peptilogics, a biotechnology platform company that develops best-in-class novel peptide drugs for unmet medical needs. He also has a PhD in Biochemistry and Molecular Genetics from the University of Pittsburgh’s School of Medicine.

 

Amongst other problems, his company Peptilogics is focused on developing a new category of antibiotics. It has been 20 years since there was a genuinely new class of antibiotics, yet bacterial cells have continued to evolve and develop into drug-resistant infections.

 

In this interview, Jonathan and Aaron discuss the founding of Peptilogics, why they’re focused on this new modality of medication, and the FDA approval process.

 

Sign up for a Weekly Email that will Expand Your Mind.

 

Jonathan Steckbeck’s Challenge; If there’s something that you want to do that doesn’t exist, go do it.

 

Connect with Jonathan Steckbeck

Linkedin

Peptilogics Website

 

If you liked this interview, check out episode 456 with Pete DeComo where we discuss the long, arduous process of developing a medical device and episode 443 with Blake Dube where we talk about better oxygen tanks.

 

Text Me What You Think of This Episode 412-278-7680

Underwritten by Piper Creative

Piper Creative makes creating podcasts, vlogs, and videos easy. 

 

How? Click here and Learn more.

 

We work with Fortune 500s, medium-sized companies, and entrepreneurs.

 

Follow Piper as we grow

YouTube

Instagram

Subscribe on iTunes | Stitcher | Overcast | Spotify